(Q31440110)

2 July 2017

1 reference

title

Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure (English)

1 reference

2 July 2017

1 reference

Lehtonen L

1

1 reference

2 July 2017

publication date

1 May 2000

1 reference

Current cardiology reports

2 July 2017

published in

1 reference

2 July 2017

volume

2

1 reference

2 July 2017

issue

3

1 reference

2 July 2017

page(s)

233-243

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-000-0074-6

2 July 2017

exact match

0 references

cites work

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11886-000-0074-6

Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11886-000-0074-6

Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11886-000-0074-6

Site dependent bioavailability and metabolism of levosimendan in dogs

21 January 2018

1 reference

12 December 2020

Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study.

1 reference

12 December 2020

Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.

1 reference

12 December 2020

Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties.

1 reference

12 December 2020

Parenteral inotropic support for advanced congestive heart failure

1 reference

12 December 2020

Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial

1 reference

12 December 2020

Haemodynamic dose-efficacy of levosimendan in healthy volunteers.

1 reference

12 December 2020

Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?

1 reference

12 December 2020

Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart

1 reference

12 December 2020

Surviving heart failure: Robert L. Frye lecture

1 reference

12 December 2020

Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.

1 reference

12 December 2020

Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.

1 reference

12 December 2020

Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers*

1 reference

12 December 2020

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

12 December 2020

Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial.

1 reference

12 December 2020

Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart

1 reference

12 December 2020

Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function

1 reference

12 December 2020

The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan

1 reference

12 December 2020

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

12 December 2020

Safety of levosimendan and other calcium sensitizers

1 reference

12 December 2020

The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells.

1 reference

12 December 2020

Drug binding to cardiac troponin C

1 reference

12 December 2020

Mechanisms of action of calcium-sensitizing drugs

1 reference

12 December 2020

Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy

1 reference

12 December 2020

Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock

1 reference

12 December 2020

Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency

1 reference

12 December 2020

Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.

1 reference

12 December 2020

Mechanisms of the contractile effects of levosimendan in the mammalian heart

1 reference

12 December 2020

Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts

1 reference

12 December 2020

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

1 reference

12 December 2020

Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure

1 reference

12 December 2020

Effects of levosimendan on myocardial contractility and oxygen consumption

1 reference

12 December 2020

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

1 reference

12 December 2020

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

1 reference

12 December 2020

Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels

1 reference

12 December 2020

Hemodynamic effects of calcium-sensitizing agents

1 reference

12 December 2020

Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.

1 reference

12 December 2020

Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure.

1 reference

12 December 2020

Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril

1 reference

12 December 2020

Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals

1 reference

12 December 2020

Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed?

1 reference

12 December 2020

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

1 reference

12 December 2020

Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit

1 reference

12 December 2020

Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device

1 reference

12 December 2020

Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation

1 reference

12 December 2020

Intracoronary levosimendan enhances contractile function of stunned myocardium

1 reference

12 December 2020

Classification of positive inotropic agents

1 reference

12 December 2020

Levosimendan potentiates the inotropic actions of dopamine in conscious dogs

1 reference

12 December 2020

10.1007/S11886-000-0074-6

Identifiers

DOI

1 reference

Dimensions Publication ID

2 July 2017

1022363198

0 references

1 reference